Drug-resistant primary cell lines were re-sensitised by combination treatment with the FGFR inhibitor AZD4547—we prioritise extension of this clinical series as our DOCS study matures, and suggest that assessment of individuality in tumour and/or ascites FGF1 expression may have future clinical utility in patient selection for combination chemotherapy/FGFR inhibitor treatment. The gene discussed is FGF1; the disease is neoplasm.